Retrospective analysis of the pharmaco-utilization of VEGF inhibitors and health care costs among patients with wet age-related macular degeneration and other …
V Perrone, M Dovizio, C Veronesi, R Citraro… - International Journal of …, 2022 - mdpi.com
This Italian retrospective study aimed to analyze the pharmaco-utilization of anti-VEGF drugs
and health care costs among patients with wet age-related macular degeneration (wAMD) or …
and health care costs among patients with wet age-related macular degeneration (wAMD) or …
Evaluation of the Effect of Naringenin Liposomal Formulation on Retinopathy in an Experimental Rabbit Model
A Salimi, BS Makhmalzadeh, M Feghhi… - KAFKAS …, 2022 - vetdergikafkas.org
Neovascularization is a hallmark of diabetic retinopathy (DR). Naringenin has protective
effect against DR. Liposomes are suitable Nano-carriers for ocular drug delivery. Hence, we …
effect against DR. Liposomes are suitable Nano-carriers for ocular drug delivery. Hence, we …
[HTML][HTML] Preparation and Characterization of Ozonated Liposomes Loaded with Curcumin: A Potential Approach for Diabetic Retinopathy Treatment
HH Kaydan, M Feghhi, A Rezaei, F Bagheri… - Jundishapur Journal of … - brieflands.com
Background: Limitations in drug penetration are overcome by nanotechnology, particularly
liposomes, which enhance targeted administration of ocular medications. Liposomes can …
liposomes, which enhance targeted administration of ocular medications. Liposomes can …
A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?
CM Dintsios - Expert Review of Pharmacoeconomics & Outcomes …, 2022 - Taylor & Francis
Objective To analyze how ophthalmic drugs fared in the early benefit assessment (EBA)
after its introduction in Germany up to 2020 and to quantify its impact on their negotiated …
after its introduction in Germany up to 2020 and to quantify its impact on their negotiated …
[PDF][PDF] Bevacizumab
JM Cortalezzi - Oftalmología Clínica y Experimental, 2021 - revistaoce.com
El Avastin® es el nombre comercial de un fármaco llamado bevacizumab, que es un
anticuerpo monoclonal inicialmente desarrollado, utilizado y aprobado en 2004 por la FDA …
anticuerpo monoclonal inicialmente desarrollado, utilizado y aprobado en 2004 por la FDA …
[PDF][PDF] Fármacos utilizados para dmae neovascular Bevacizumab
JM Cortalezzi - Archivos Argentinos de Oftalmología, 2021 - archivosoftalmologia.com.ar
El Avastin® es el nombre comercial de un fármaco llamado bevacizumab, que es un
anticuerpo monoclonal inicialmente desarrollado, utilizado y aprobado en 2004 por la FDA …
anticuerpo monoclonal inicialmente desarrollado, utilizado y aprobado en 2004 por la FDA …
[PDF][PDF] Fármacos utilizados para dmae neovascular: Ranibizumab
M Irós - Archivos Argentinos de Oftalmología, 2021 - archivosoftalmologia.com.ar
El Avastin® es el nombre comercial de un fármaco llamado bevacizumab, que es un
anticuerpo monoclonal inicialmente desarrollado, utilizado y aprobado en 2004 por la FDA …
anticuerpo monoclonal inicialmente desarrollado, utilizado y aprobado en 2004 por la FDA …